NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
ID: 353821Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353821

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-002.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NHLBI Outstanding Investigator Award (OIA), a federal grant aimed at enhancing scientific productivity and innovation in heart, lung, blood, and sleep (HLBS) research. This award is designed for experienced Program Directors/Principal Investigators (PDs/PIs) who currently hold at least two NHLBI R01-equivalent awards, providing long-term funding for up to seven years to support their research programs rather than specific projects. The OIA is significant as it allows researchers greater flexibility to explore innovative research directions while reducing the administrative burden associated with managing multiple grants. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by April 28, 2027, and an anticipated funding amount of up to $20 million annually across multiple fiscal years.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HL-26-002.html
    The National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute (NHLBI) announces the NHLBI Outstanding Investigator Award (OIA), aimed at fostering scientific productivity and innovation in heart, lung, blood, and sleep (HLBS) research. This award will provide long-term funding for up to seven years to experienced researchers currently holding at least two NHLBI R01-equivalent awards or are in the 6th or 7th year of an NHLBI R35 award. The OIA is designed to support a researcher’s program rather than specific projects, allowing greater flexibility to explore new research avenues and reduce the administrative burden of managing multiple grants. With an anticipated funding of up to $20 million annually across multiple fiscal years, the program targets established investigators capable of making significant contributions to HLBS research. Key components of eligibility include a strong research track record, a commitment of substantial effort on the proposed research, and relinquishment of existing individual research project grants upon receiving the OIA. Applications are due by early 2025, with proposals undergoing rigorous peer review to assess their scientific merit and potential impact in the field. The NIH emphasizes supporting diversity within the research community and encourages applicants from various backgrounds to apply.
    Similar Opportunities
    NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Emerging Investigator Award (EIA), a federal grant designed to support experienced researchers in heart, lung, blood, and sleep (HLBS) health research. This award aims to promote scientific productivity and innovation by providing long-term funding for research programs, allowing Principal Investigators (PIs) to explore groundbreaking ideas without the constraints of specific project aims. Eligible applicants must currently hold at least two NHLBI R01-equivalent awards and commit a minimum of six person-months to their research, with funding requests up to $700,000 per year and a total anticipated commitment of $20 million annually. Interested parties should submit their applications by April 28, 2027, and can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Career Transition Award (K22), a federal grant aimed at supporting postdoctoral fellows and doctoral-level researchers transitioning from intramural NIH research to independent extramural research. This program features a two-phase support structure: an up to two-year mentored intramural phase followed by a three-year extramural phase, contingent upon a successful review of the awardee's research progress. The grant is designed to cultivate future researchers capable of addressing critical health-related questions and enhancing the scientific community, with an emphasis on diversity and inclusion of underrepresented groups. Interested applicants must have a relevant doctoral degree and adhere to stringent application instructions, with proposals due starting September 12, 2024. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is open until July 12, 2027.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders," aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This grant (R61/R33) facilitates funding for essential preclinical activities and the execution of clinical trials, structured in two phases: the R61 phase focuses on preparatory tasks, while the R33 phase involves the actual trial conduct, guided by specific milestones. This initiative is crucial for advancing research that addresses significant health challenges associated with HLBS disorders. Interested applicants can submit proposals starting January 3, 2025, with a maximum project period of five years, and should direct inquiries to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html.
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Trial Pilot Studies (R34 Clinical Trial Optional) through the National Heart, Lung, and Blood Institute (NHLBI). This initiative aims to support research that provides essential information for the design of future Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders, requiring applicants to demonstrate the scientific necessity and sufficiency of their proposed studies. The NHLBI emphasizes inclusivity by mandating a Plan for Enhancing Diverse Perspectives (PEDP) to enhance the project's scientific merit, with a budget of up to $450,000 in direct costs available over a maximum project period of three years. Interested applicants should note that the application period opens on January 16, 2025, and the final submission deadline is January 7, 2027; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Career Transition Award (K22) aimed at supporting postdoctoral fellows and research trainees in transitioning their research programs to extramural institutions as junior investigators. This grant provides a structured five-year program, which includes a mentored intramural phase of up to two years followed by an independent extramural phase lasting three years, contingent upon successful progress during the mentored phase. The program is designed to cultivate a diverse pool of skilled investigators to meet national biomedical research needs, with eligibility requirements including a doctoral degree and a maximum of five years of postdoctoral research experience within the NHLBI. Interested applicants should note that the application deadline is July 12, 2027, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-209.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting Phase I clinical trials for therapeutic and diagnostic interventions related to heart, lung, blood, and sleep (HLBS) disorders. This initiative seeks to accelerate the development of clinical interventions by funding investigator-initiated studies that demonstrate potential advancements in HLBS health, with a focus on ensuring that applicants are prepared to initiate trials promptly after receiving funding. The funding is capped at $1.5 million per year for a project period of up to three years, contingent on satisfactory progress and milestone completion, with applications opening on January 3, 2025, and the first due date set for February 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html.